Title: The profile of the key pro-inflammatory cytokines in the serum of patients with CD and
their association with the disease severity and activity
Version: 6 Date: 16 Oct 2022
Reviewer:  Gilles R. G. Monif
Reviewer's report:
The updated manuscript now reflects a better understanding of the events that combine to
produce disease.  Thank you. Given the ability of biologics to preclude cytokine/ MAP
cytotoxicity,  a positive dose clinical response correlation was to have be anticipated .
According to its FDA filing,  Humira(R) had been able to induce a temporary remission in
40% of study patients . In 60% of study patients, it was failed therapy. Dietary exclusion
of foods potentially adulterated by MAP has been shown to produce superior outcomes
to those initially achieved with a biologic (J. Crohn Colitis 11:1205-1212. 2017; World J.
Gastroenterol. 16;2484-2495.2014). What is lacking to date is a comprehensive, randomized,
blinded, comparison between MAP exclusion diet/initial antibiotic coverage and biologics.
Humira(R) and its  current re-formulation  is the globally the number one or two revenue
producing drugs.  Administering added drug will increase cost.
Title: The profile of the key pro-inflammatory cytokines in the serum of patients with CD and
their association with the disease severity and activity
Version: 6 Date: 16 Oct 2022
Reviewer:  Gilles R. G. Monif
Reviewer's report:
The updated manuscript now reflects a better understanding of the events that combine to
produce disease.  Thank you. Given the ability of biologics to preclude cytokine/ MAP
cytotoxicity,  a positive dose clinical response correlation was to have be anticipated .
According to its FDA filing,  Humira(R) had been able to induce a temporary remission in
40% of study patients . In 60% of study patients, it was failed therapy. Dietary exclusion
of foods potentially adulterated by MAP has been shown to produce superior outcomes
to those initially achieved with a biologic (J. Crohn Colitis 11:1205-1212. 2017; World J.
Gastroenterol. 16;2484-2495.2014). What is lacking to date is a comprehensive, randomized,
blinded, comparison between MAP exclusion diet/initial antibiotic coverage and biologics.
Humira(R) and its  current re-formulation  is the globally the number one or two revenue
producing drugs.  Administering added drug will increase cost.
Please review this paper.
user
Title: The profile of the key pro-inflammatory cytokines in the serum of patients with CD and
their association with the disease severity and activity
Version: 6 Date: 16 Oct 2022
Reviewer:  Gilles R. G. Monif
Reviewer's report:
The updated manuscript now reflects a better understanding of the events that combine to
produce disease.  Thank you. Given the ability of biologics to preclude cytokine/ MAP
cytotoxicity,  a positive dose clinical response correlation was to have be anticipated .
According to its FDA filing,  Humira(R) had been able to induce a temporary remission in
40% of study patients . In 60% of study patients, it was failed therapy. Dietary exclusion
of foods potentially adulterated by MAP has been shown to produce superior outcomes
to those initially achieved with a biologic (J. Crohn Colitis 11:1205-1212. 2017; World J.
Gastroenterol. 16;2484-2495.2014). What is lacking to date is a comprehensive, randomized,
blinded, comparison between MAP exclusion diet/initial antibiotic coverage and biologics.
Humira(R) and its  current re-formulation  is the globally the number one or two revenue
producing drugs.  Administering added drug will increase cost.
assistant